Yongtai Technology's subsidiary secures drug registration certificate

Zhejiang Yongtai Technology (SZSE:002326) announced that its wholly-owned subsidiary, Zhejiang Yongtai Pharmaceutical Co., Ltd., has been granted a drug registration certificate by the National Medical Products Administration for Vonoprazan Fumarate Tablets. The approved drug, categorized as a Class 4 chemical drug, is available in 10mg and 20mg specifications and is indicated for treating acid-related diseases like reflux esophagitis and ulcers. This approval allows Yongtai Pharmaceutical to market the drug in China and expands the company's product line. The original drug is produced by Takeda Pharmaceutical. While the approval is expected to positively impact Yongtai Technology's performance, the company cautions that pharmaceutical products are subject to market and policy uncertainties.